LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 454

Search options

  1. Article ; Online: TAK-003 dengue vaccine as a new tool to mitigate dengue in countries with a high disease burden.

    Wilder-Smith, Annelies

    The Lancet. Global health

    2024  Volume 12, Issue 2, Page(s) e179–e180

    MeSH term(s) Humans ; Dengue Vaccines ; Dengue/epidemiology ; Dengue/prevention & control ; Dengue Virus ; Cost of Illness
    Chemical Substances Dengue Vaccines
    Language English
    Publishing date 2024-01-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(23)00590-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005.

    Wilder-Smith, Annelies

    The Journal of clinical investigation

    2024  Volume 134, Issue 3

    Abstract: Dengue fever, caused by four distinct serotypes of the dengue virus (DENV1-4), poses a public health concern for much of the world. The NIH's Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) has ... ...

    Abstract Dengue fever, caused by four distinct serotypes of the dengue virus (DENV1-4), poses a public health concern for much of the world. The NIH's Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) has developed a series of single-dose, live-attenuated tetravalent DENV vaccines, including TV005. However, phase III trials require a lengthy three-to-five year follow-up. In contrast, controlled human infection models (CHIMs) offer a faster means to assess vaccine efficacy for any of the four serotypes. In this issue of the JCI, Pierce, Durbin, and colleagues conducted a CHIM study with attenuated DENV2 and DENV3 challenge viruses in individuals six months after vaccination with TV005. The TV005 vaccine was well tolerated and effectively protected all vaccinated individuals from viremia and rash during challenges with DENV2 or DENV3. Notably, vaccine recipients also showed serotype-specific efficacy. While long-term studies are still needed, these findings represent an important step in providing protection against dengue virus.
    MeSH term(s) Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; Dengue/prevention & control ; Dengue Vaccines ; Dengue Virus ; Vaccination ; Vaccines, Attenuated ; Clinical Trials, Phase III as Topic
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Dengue Vaccines ; Vaccines, Attenuated
    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI177610
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Determining force of infection for chikungunya to support vaccine policy development.

    Wilder-Smith, Annika Beate / Wilder-Smith, Annelies

    The Lancet. Infectious diseases

    2024  Volume 24, Issue 5, Page(s) 441–442

    MeSH term(s) Humans ; Chikungunya Fever/prevention & control ; Chikungunya virus/immunology ; Health Policy ; Vaccine Development ; Viral Vaccines
    Chemical Substances Viral Vaccines
    Language English
    Publishing date 2024-02-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(24)00062-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Dengue-in-Dhaka Initiative: results from a phase 2 trial evaluating the TV005 tetravalent dengue vaccine in Bangladesh.

    Wilder-Smith, Annelies

    The Lancet. Infectious diseases

    2023  Volume 24, Issue 2, Page(s) 112–113

    MeSH term(s) Humans ; Dengue Vaccines ; Bangladesh/epidemiology ; Dengue/epidemiology ; Dengue/prevention & control ; Dengue Virus ; Antibodies, Viral ; Vaccines, Attenuated
    Chemical Substances Dengue Vaccines ; Antibodies, Viral ; Vaccines, Attenuated
    Language English
    Publishing date 2023-09-27
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(23)00565-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Dengue vaccine development: challenges and prospects.

    Wilder-Smith, Annelies

    Current opinion in infectious diseases

    2022  Volume 35, Issue 5, Page(s) 390–396

    Abstract: Purpose of review: Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines.: ... ...

    Abstract Purpose of review: Dengue vaccine development is a high public health priority. To date, no dengue vaccine is in widespread use. Here we review the challenges in dengue development and the latest results for the second-generation dengue vaccines.
    Recent findings: The biggest hurdle is the immunological interaction between the four antigenically distinct dengue serotypes. The advantages of second-generation dengue vaccines are the inclusion of nonstructural proteins of the dengue backbone and a more convenient dosing with reduced numbers of doses needed.
    Summary: Although dengue-primed individuals can already benefit from vaccination with the first licensed dengue vaccine CYD-TDV, the public health need for the dengue-naive population has not yet been met. The urgent need remains to identify correlates of both protection and enhancement; until such correlates have been identified, all second-generation dengue vaccines still need to go through full phase 3 trials. The 5-year efficacy and safety data for both second-generation dengue vaccines are imminent.
    MeSH term(s) Dengue Vaccines ; Humans ; Public Health ; Vaccination/methods
    Chemical Substances Dengue Vaccines
    Language English
    Publishing date 2022-09-13
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 645085-4
    ISSN 1473-6527 ; 1535-3877 ; 0951-7375 ; 1355-834X
    ISSN (online) 1473-6527 ; 1535-3877
    ISSN 0951-7375 ; 1355-834X
    DOI 10.1097/QCO.0000000000000871
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Promising efforts to develop an mRNA vaccine against Zika.

    Wilder-Smith, Annelies / Durbin, Anna

    The Lancet. Infectious diseases

    2023  Volume 23, Issue 5, Page(s) 520–522

    MeSH term(s) Humans ; Zika Virus/genetics ; Zika Virus Infection/prevention & control ; Vaccines, Synthetic ; Viral Vaccines ; Antibodies, Viral ; Antibodies, Neutralizing ; mRNA Vaccines
    Chemical Substances Vaccines, Synthetic ; Viral Vaccines ; Antibodies, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-01-19
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(22)00827-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Conference proceedings: Meningococcal disease

    Wilder-Smith, Annelies

    [presentations given during the First International Conference on Thymic Malignancies held on August 20 - 21, 2009 ... in Bethesda, MD]

    (Journal of travel medicine ; 17, Suppl. 1)

    2010  

    Event/congress International Conference on Thymic Malignancies (1, 2009, BethesdaMd.)
    Author's details guest ed.: Annelies Wilder-Smith
    Series title Journal of travel medicine ; 17, Suppl. 1
    Collection
    Language English
    Size 25 S. : graph. Darst., Kt.
    Publisher Decker
    Publishing place Hamilton, ON
    Publishing country Canada
    Document type Book ; Conference proceedings
    HBZ-ID HT016563727
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  8. Article ; Online: The expanding geographic range of dengue in Australia.

    Wilder-Smith, Annelies

    The Medical journal of Australia

    2021  Volume 215, Issue 4, Page(s) 171–172

    MeSH term(s) Australia/epidemiology ; Dengue/epidemiology ; Humans
    Language English
    Publishing date 2021-07-20
    Publishing country Australia
    Document type Editorial ; Comment
    ZDB-ID 186082-3
    ISSN 1326-5377 ; 0025-729X
    ISSN (online) 1326-5377
    ISSN 0025-729X
    DOI 10.5694/mja2.51185
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Dengue during the COVID-19 pandemic.

    Wilder-Smith, Annelies

    Journal of travel medicine

    2021  Volume 28, Issue 8

    MeSH term(s) COVID-19 ; Dengue/epidemiology ; Dengue Virus ; Humans ; Pandemics ; SARS-CoV-2
    Language English
    Publishing date 2021-11-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 1212504-0
    ISSN 1708-8305 ; 1195-1982
    ISSN (online) 1708-8305
    ISSN 1195-1982
    DOI 10.1093/jtm/taab183
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?

    Wilder-Smith, Annelies

    The Lancet. Infectious diseases

    2021  Volume 22, Issue 2, Page(s) 152–153

    MeSH term(s) COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines
    Chemical Substances COVID-19 Vaccines ; Vaccines
    Language English
    Publishing date 2021-10-29
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(21)00690-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top